INTECH BIOPHARM LTD.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 82
- Market Cap
- -
Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90mcg Per Actuation in Healthy Volunteers Under Fasting Conditions
Not Applicable
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05300087
- Locations
- 🇨🇳
Tamshui Mackay Memorial Hospital, New Taipei City, Taiwan
Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 270
- Registration Number
- NCT05152355
- Locations
- 🇨🇳
The Second Hospital of Hebei Medical University, Shijia Zhuang, He Bei Sheng, China
🇨🇳Bao Gang Hospital, Baotou, Inner Mongolia, China
🇨🇳The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China
Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients with Stable Mild Asthma
Not Applicable
Recruiting
- Conditions
- Mild Asthma
- Interventions
- Other: Albuterol Sulfate inhalation PlaceboOther: Methacholine
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT04912596
- Locations
- 🇮🇳
Dr. Jivraj Mehta Smarak Health Foundation, Ahmedabad, India
🇮🇳KLEs Dr Prabhakar Kore Hospital & MRC, Belagave, India
🇮🇳NRS Medical College and Hospital, Kolkata, India
Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions
Not Applicable
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04803734
- Locations
- 🇨🇳
Tamshui Mackay Memorial Hospital, New Taipei City, Taiwan
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT04494321
- Locations
- 🇨🇳
Clinical Pharmacology Unit of Mackay Memorial Hospital Tamshui Branch, New Taipei City, Taiwan
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block
Phase 1
Completed
- Conditions
- AsthmaChronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT02850484
Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block
Phase 1
Completed
- Conditions
- AsthmaChronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT02466347
- Locations
- 🇨🇳
Clinical Pharmacology Unit of Mackay Memorial Hospital Tamshui Branch, New Taipei City, Taiwan
Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block
Phase 1
Completed
- Conditions
- AsthmaChronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2015-06-09
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT02466503
- Locations
- 🇨🇳
Clinical Pharmacology Unit of Mackay Memorial Hospital Tamshui Branch, New Taipei City, Taiwan
Multiple-dose Pharmacokinetics Study of "SYN006 HFA MDI" Administered Orally to Healthy Volunteers
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: Budesonide/Procaterol 180/10 X 4 puffs
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02165033
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Neihu, Taiwan
Bioavailability Study of SYN006, Pulmicort pMDI and Meptin Air in Healthy Adult.
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)Asthma
- Interventions
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02165046
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath